

CANCER GENOMICS & PROTEOMICS

online from January 2009
 HighWire Press®
 STANFORD UNIVERSITY

www.cgp-journal.com

Print ISSN: 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 2 (2005) - VOL. 3 (2006)

VOL. 4 (2007) - VOL. 5 (2008) - VOL. 6 (2009)

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 2-4 months from submission or 1-2 months from acceptance.

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PUBMED, *^oDLINE, CAS (Chemical Abstracts Service); BIOLOGICAL ABSTRACTS; EMBASE and BIOBASE, Compendex, GEOBASE, EMBiology, FLUIDEX, Scopus (Elsevier Bibliographic Databases); BIOSIS PREVIEWS; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal, PubsHub, SIIC.

Editorial Office: International Institute of Anticancer Research

1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece.

Tel: +30 22950 52945, Fax: +30 22950 53389

e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org, editor@cgp-journal.com (Managing Editor)

A Selection of Recent Papers

Proteomic Analysis of Archival Breast Cancer Serum. B.A ZEIDAN, R.I. CUTRESS, N. MURRAY, G. COULTON, C. HASTIE, G. PACKHAM, P.A. TOWNSEND (*Southampton; Gosport; London; Portsmouth, UK*)

MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines. X. LIU, J. YU, L. JIANG, A. WANG, F. SHI, H. YE, X. ZHOU (*Chicago, IL, USA; Guangzhou, China*)

Increased levels of macrophage-secreted Cathepsin S during prostate cancer progression in TRAMP mice and patients. C. LINDAHL, M. SIMONSSON, A. BERGH, E. THYSELL, H. ANTTI, M. SUND, P. WIKSTRÖM (*Umeå, Sweden*)

Effect of Expressional Alteration of KAI1 on Breast Cancer Cell Growth, Adhesion, Migration and Invasion. F.A. MALIK, A.J SANDERS, M.A. KAYANI, W.G. JIANG (*Cardiff, Wales, UK; Islamabad, Pakistan*)

Gene Expression Profiling in Response to Estradiol and Genistein in Ovarian Cancer Cells. L. P. PARKER, D.D. TAYLOR, S. KERSTERSON, C. GERCEL-TAYLOR (*Louisville KY, USA*)

Differences in mRNA and microRNA Microarray Expression Profiles in Human Colon Adenocarcinoma HT-29 Cells Treated with either Intensity-modulated Radiation Therapy (IMRT), or Conventional Radiation Therapy (RT). F.E. AHMED, P.W. VOS, C. JEFFRIES, J.E. WILEY, D.A. WEIDNER, H. MOTA, C. BONNERUP (*Greenville; Chapel Hill, NC, USA*)

Chromosomal Alterations and Mutagen Sensitivity in Human Mucosal Cells of the Oropharynx and Lymphocytes caused by BPDE. M. REITER, P. BAUMEISTER, S. ZIEGER, U. HARRÉUS (*Munich, Germany*)

Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer. N. VALERI, C.M. CROCE, M. FABBRI (*Columbus, OH, USA; Ferrara; Meldola, Italy*)

PGF Isoforms, PLGF-1 and PGF-2, in Colorectal Cancer and the Prognostic Significance. A. ESCUDERO-ESPARZA, T.A. MARTIN, M.L. DAVIES, W.G. JIANG (*Cardiff, UK*)

MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas. M. MELLAI, V. CALDERA, L. ANNOVAZZI, A. CHIÒ, M. LANOTTE, P. CASSONI, G. FINOCCHIARO, D. SCHIFFER (*Turin; Milan, Italy*)

Gene Expression Analysis of HCT116 Colon Tumor Derived Cells Treated with the Polyamine Analog PG-11047. N.A. IGNATENKO H.F. YERUSHALMI, R. PANDEY, K.L. KACHEL, D.E. STRINGER, L.J. MARTON, E.W. GERNER (*Tucson, AZ; Redwood City, CA, USA; Haifa, Israel*)

Diagnosis of Breast Cancer by Tear Proteomic Pattern. A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, R.L. SCHWIRZ, F.H. GRUS (*Mainz, Germany*)

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios

International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

online from January 2009



in vivo

International Journal of Experimental and Clinical
Pathophysiology and Drug Research

Published by the International Institute of Anticancer Research

ISSN: 0258-851X

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389. e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IAR and the conferences please visit the IAR website: www.iiar-anticancer.org

Selection of Recent Articles

Circulating Cytokine Levels In Prostate Cancer Patients Undergoing Radiation Therapy: Influence Of Neoadjuvant Total Androgen Suppression. R.M. JOHNKE J.M. EDWARDS, M.J. EVANS, G.N. NANGAMI, N.T.G. BAKKEN, J.M. KILBURN, T.-K. LEE, R.R. ALLISON, U.L. KARLSSON, H.H. ARASTU (*Greenville, NC, USA*)

Transgenic Mice Expressing Constitutively Active Akt in Oral Epithelium Validate Klf4 as a Potential Biomarker of Head and Neck Squamous Cell Carcinoma. M. MORAL, C. SEGRELLES, A.B. MARTÍNEZ-CRUZ, C. LORZ, *et al.* (*Madrid, Spain; Smithville, TX, USA*)

Detection of Herpesviruses and Parvovirus B19 in Gastric and Intestinal Mucosa of Chronic Fatigue Syndrome Patients. M. FRÉMONT, K. METZGER, H. RADY, J. HULSTAERT, K. DE MEIRLEIR (*Zellik; Brussels; Vilvoorde, Belgium*)

A Bioluminescent Orthotopic Mouse Model of Human Osteosarcoma that Allows Sensitive and Rapid Evaluation of New Therapeutic Agents In Vivo. K.E. COMSTOCK, C.L. HALL, S. DAIGNAULT, S.A. MANDLEBAUM, C. YU, E.T. KELLER (*Ann Arbor, MI, USA*)

Obesity Impairs Wound Healing in Ovariectomized Female Mice. V.B. HOLCOMB, V.A. KECK, J.C. BARRETT, J. HONG, S.K. LIBUTTI, N.P. NÚÑEZ (*Austin, TX; Bethesda, MD; Cambridge, MA; Bronx, NY, USA*)

Effectiveness of Combined Modality Radiotherapy of Orthotopic Human Squamous Cell Carcinomas in Nu/Nu Mice Using Cetuximab, Tirapazamine, and MnSOD-Plasmid Liposome Gene Therapy. M.W. EPPERLY, S.M. LAI, N. MASON, B. LOPRESI, T. DIXON, D. FRANICOLA, Y. NIU, W.R. WILSON, A.J. KANAI, J.S. GREENBERGER (*Pittsburgh, PA, USA; Auckland, New Zealand*)

Inhibiting Platelet Derived Growth Factor Beta (PDGFR-B) Decreases Ewing's Sarcoma Growth and Metastasis in a Novel Orthotopic Human Xenograft Model. Y.X. WANG, D. MANDAL, S. WANG, D. HUGHES, R.E. POLLOCK, D. LEV, E. KLEINERMAN, A. HAYES-JORDAN (*Houston, TX; Kingston, RI, USA*)

Ethyl-eicosapentaenoic Acid Reduces Liver Lipids and Lowers Plasma Levels of Lipids in Mice fed a High-fat Diet. N. NEMOTO, S. SUZUKI, H. KIKUCHI, H. OKABE, S. SASSA, S. SAKAMOTO (*Chiba; Tokyo, Japan*)

Management of Pseudomyxoma Peritonei by Cytoreduction+HIPEC (Hyperthermic Intraperitoneal Chemotherapy): Results Analysis of a Twelve-Year Experience. M. VAIRA, T. CIOPPA, G. DE MARCO, C. BING, S. D'AMICO, M. D'ALESSANDRO, G. FIORENTINI, M. DE SIMONE (*Florence; Italy*)

Dietary Calcium Source Influences Body Composition, Glucose Metabolism and Hormone Levels in a Mouse Model of Postmenopausal Obesity. R.E. DE ANGEL, D. BERRIGAN, N.P. NÚÑEZ, S.D. HURSTING, S.N. PERKINS (*Austin; Smithville, TX; Bethesda, MD, USA*)

Distribution of [³H]-Corticosterone in Urine, Feces and Blood of Male Sprague-Dawley Rats After Tail Vein and Jugular Vein Injections. K.S.P. ABELSON, S.S. FARD, J. NYMAN, R. GOLDKUHL, J. HAU (*Uppsala, Sweden; Copenhagen, Denmark*)

5-Hydroxymethylfurfural and 5-Sulfooxymethylfurfural Increase Adenoma and Flat ACF Number in the Intestine of Min/+ Mice. C. RØNNINGBORG, T. HUS-Y, H. GLATT, J.E. PAULSEN, J. ALEXANDER (*Oslo, Norway; Nuthetal, Germany*)

Ocular Toxicity Caused by Paclitaxel in Neonatal Sprague-Dawley Rats. M. KUWATA, K. YOSHIZAWA, M. MATSUMURA, K. TAKAHASHI, A. TSUBURA (*Osaka, Japan*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

Vitamin D-24-Hydroxylase in Benign and Malignant Breast Tissue and Cell Lines. D. FISCHER, S. BECKER, T. CORDES, B. BÜCKER, K. DIEDRICH, M. FRIEDRICH, D. SALEHIN, M. THILL (<i>Lübeck; Krefeld, Germany</i>)	3641
Cross-talk between Vitamin D Receptor (VDR)- and Peroxisome Proliferator-activated Receptor (PPAR)-signaling in Melanoma Cells. P. SERTZNIG, T. DUNLOP, M. SEIFERT, W. TILGEN, J. REICHRATH (<i>Homburg/Saar, Germany; Kuopio, Finland</i>)	3647
Expression of 25-Hydroxyvitamin D-1 α -Hydroxylase (1 α OHase, <i>CYP27B1</i>) Splice Variants in HaCaT Keratinocytes and Other Skin Cells: Modulation by Culture Conditions and UV-B Treatment <i>In Vitro</i> . M. SEIFERT, W. TILGEN, J. REICHRATH (<i>Homburg, Germany</i>)	3659
Reduced Serum 25-Hydroxyvitamin D Levels in Stage IV Melanoma Patients. B. NÜRNBERG, S. GRÄBER, B. GÄRTNER, J. GEISEL, C. PFÖHLER, D. SCHADENDORF, W. TILGEN, J. REICHRATH (<i>Homburg; Essen, Germany</i>)	3669
* Review: How to Optimize Vitamin D Supplementation to Prevent Cancer, Based on Cellular Adaptation and Hydroxylase Enzymology. R. VIETH (<i>Toronto, ON, Canada</i>)	3675
Part B	
Preface: Vitamin D, Calcium, and Cancer. H.S. CROSS, M. PETERLIK (<i>Vienna, Austria</i>)	3685
* Review: Calcium, Vitamin D and Cancer. M. PETERLIK, W.B. GRANT, H.S. CROSS (<i>Vienna, Austria; San Francisco, CA, USA</i>)	3687
* Review: Epidemiology of Vitamin D Insufficiency and Cancer Mortality. S. PILZ, A. TOMASCHITZ, B. OBERMAYER-PIETSCH, H. DOBNIG, T.R. PIEBER (<i>Graz, Austria</i>)	3699
* Review: Modulation of Vitamin D Synthesis and Catabolism in Colorectal Mucosa: A New Target for Cancer Prevention. H.S. CROSS, T. NITTKE, M. PETERLIK (<i>Vienna, Austria</i>)	3705
The Dependency of Vitamin D Status on Body Mass Index, Gender, Age and Season. Z. LAGUNOVA, A.C. POROJNICU, F. LINDBERG, S. HEXEBERG, J. MOAN (<i>Oslo, Norway</i>)	3713
Mutual Associations between Malignancy, Age, Gender, and Subsite Incidence of Colorectal Cancer. W. BROZEK, S. KRIWANEK, E. BONNER, M. PETERLIK, H.S. CROSS (<i>Vienna, Austria</i>)	3721
Parallel Elevation of Colonic 1,25-Dihydroxyvitamin D ₃ Levels and Apoptosis in Female Mice on a Calcium-deficient Diet. T. NITTKE, E. KALLAY, T. MANHARDT, H.S. CROSS (<i>Vienna, Austria</i>)	3727
* Reviews (pages 3471, 3485, 3495, 3501, 3511, 3597, 3675, 3687, 3699, 3705)	

Air Pollution in Relation to U.S. Cancer Mortality Rates: An Ecological Study; Likely Role of Carbonaceous Aerosols and Polycyclic Aromatic Hydrocarbons. W.B. GRANT (<i>San Francisco, CA, USA</i>)	3537
Evaluation of 19-Nor-2 α -(3-hydroxypropyl)-1 α ,25-dihydroxyvitamin D ₃ as a Therapeutic Agent for Androgen-dependent Prostate Cancer. J.N. FLANAGAN, S. ZHENG, K.-C. CHIANG, A. KITTAKA, T. SAKAKI, S. NAKABAYASHI, X. ZHAO, R.A. SPANJAARD, K.S. PERSONS, J.S. MATHIEU, M.F. HOLICK, T.C. CHEN (<i>Boston, MA, USA; Kaohsiung, Taiwan, ROC; Kanagawa; Toyama, Japan; Stockholm, Sweden</i>)	3547
Regulation of Steroid Receptor Expression by 1 α -Hydroxyvitamin D ₅ in Hormone-responsive Breast Cancer Cells. E.A. HUSSAIN-HAKIMJEE, R.G. MEHTA (<i>Chicago, IL, USA</i>)	3555
Synthesis and Biological Activities of 14- <i>epi</i> -MART-10 and 14- <i>epi</i> -MART-11: Implications for Cancer and Osteoporosis Treatment. A. KITTAKA, H. HARA, M. TAKANO, D. SAWADA, M.A. ARAI, K. TAKAGI, T. CHIDA, Y. HARADA, H. SAITO, K. TAKENOUCI, S. ISHIZUKA, K. HAYASHI, S. IKUSHIRO, T. SAKAKI, T. SUGIURA, T.C. CHEN (<i>Kanagawa; Tokyo; Toyama, Japan; Boston, MA, USA</i>)	3563
Synthesis of All Possible A-ring Diastereomers at the 1- and 3-Positions of 1 α ,25-Dihydroxy-2 β -(3-hydroxypropoxy)vitamin D ₃ (ED-71) Using C ₂ -Symmetrical Epoxide as a Common Starting Material. N. KUBODERA, S. HATAKEYAMA (<i>Tokyo; Nagasaki, Japan</i>)	3571
Antiproliferative and Calcemic Actions of <i>Trans</i> -Decalin CD-Ring Analogs of 1,25-Dihydroxyvitamin D ₃ . G. EELEN, L. VERLINDEN, J. LAUREYS, S. MARCELIS, P. DE CLERCQ, C. MATHIEU, R. BOUILLON, A. VERSTUYF (<i>Leuven; Ghent, Belgium</i>)	3579
Microarray Analysis of MCF-7 Breast Cancer Cells Treated with 1,25 Dihydroxyvitamin D ₃ or a 17-Methyl-D-ring Analog. E. VANOIRBEEK, G. EELEN, L. VERLINDEN, K. MARCHAL, K. ENGELEN, B. DE MOOR, I. BEULLENS, S. MARCELIS, P. DE CLERCQ, R. BOUILLON, A. VERSTUYF (<i>Leuven; Heverlee; Ghent, Belgium</i>)	3585
Fish Oil Enhances the Antiproliferative Effect of 1 α ,25-Dihydroxyvitamin D ₃ on Liver Cancer Cells. K.-C. CHIANG, K.S. PERSONS, N.W. ISTFAN, M.F. HOLICK, T.C. CHEN (<i>Kaohsiung, Taiwan, ROC; Boston, MA, USA</i>)	3591
* Review: Current Impediments to Acceptance of the Ultraviolet-B-Vitamin D-Cancer Hypothesis. W.B. GRANT, B.J. BOUCHER (<i>San Francisco, CA, USA; London, UK</i>)	3597
A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer. S. SRINIVAS, D. FELDMAN (<i>Stanford, CA, USA</i>)	3605
Expression of Prostaglandin Metabolizing Enzymes COX-2 and 15-PGDH and VDR in Human Granulosa Cells. M. THILL, S. BECKER, D. FISCHER, T. CORDES, A. HORNEMANN, K. DIEDRICH, D. SALEHIN, M. FRIEDRICH (<i>Lübeck; Krefeld, Germany</i>)	3611
Prostaglandin Metabolizing Enzymes in Correlation with Vitamin D Receptor in Benign and Malignant Breast Cell Lines. M. THILL, D. FISCHER, S. BECKER, T. CORDES, C. DITTMER, K. DIEDRICH, D. SALEHIN, M. FRIEDRICH (<i>Lübeck; Krefeld, Germany</i>)	3619
25-Hydroxyvitamin D ₃ 1 α -Hydroxylase Splice Variants in Benign and Malignant Ovarian Cell Lines and Tissue. D. FISCHER, M. THOMÉ, S. BECKER, T. CORDES, K. DIEDRICH, M. FRIEDRICH, M. THILL (<i>Lübeck; Krefeld, Germany</i>)	3627
Expression of 25-Hydroxyvitamin D ₃ -24-Hydroxylase in Benign and Malignant Ovarian Cell Lines and Tissue. D. FISCHER, M. THOMÉ, S. BECKER, T. CORDES, K. DIEDRICH, M. FRIEDRICH, M. THILL (<i>Lübeck; Krefeld, Germany</i>)	3635